Patents Issued in January 17, 2017
-
Patent number: 9545408Abstract: Kits and methods for treating disordered or infected tissue caused by a virus in a mammal involve co-administering a systemic anti-virus drug and topically administered anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogs, nucleoside analog precursors, and nucleotide analogs. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the skin surface and allow the anti-infective agent to kill viruses at the infected tissue site. The topical anti-infective composition renders the systemic anti-virus drug more efficacious and reduces the time and/or number of dosages otherwise required for the systemic anti-virus drug to treat the disordered tissue.Type: GrantFiled: August 11, 2015Date of Patent: January 17, 2017Assignee: QUADEX PHARMACEUTICALS, INC.Inventor: B. Ron Johnson
-
Patent number: 9545409Abstract: The use of 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml in pharmaceutical compositions for parenteral administration in the treatment of degenerative neuroretinal diseases of various geneses.Type: GrantFiled: September 17, 2013Date of Patent: January 17, 2017Inventor: Gleb Vladimirovich Zagorii
-
Patent number: 9545410Abstract: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid or apicomplexan protozoan with tyrosine kinase inhibitors.Type: GrantFiled: November 14, 2012Date of Patent: January 17, 2017Assignee: University of Georgia Research Foundation, Inc.Inventor: Kojo Mensa-Wilmot
-
Patent number: 9545411Abstract: The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. Methods for treating these conditions are provided comprising systemically administering an antiprogestin and contemporaneously locally administering an antiprogestin. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation.Type: GrantFiled: October 22, 2013Date of Patent: January 17, 2017Assignee: REPROS THERAPEUTICS INC.Inventors: Joseph S. Podolski, Ronald D. Wiehle
-
Patent number: 9545412Abstract: This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.Type: GrantFiled: June 8, 2015Date of Patent: January 17, 2017Assignee: UNIVERSITE D'AIX-MARSEILLEInventors: Pierre Cau, Nicolas Levy
-
Patent number: 9545413Abstract: A method of forming a compound in a subject can include: providing a composition having a prodrug compound represented by a structure of Formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the composition to a subject such that the prodrug compound has a phosphoryloxyalkyl prodrug moiety removed therefrom to form the compound in the subject and to form the separate phosphoryloxyalkyl compound. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, various cancers (e.g., bladder, breast, etc.), dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis, candidiasis (moniliasis), Candida albicans, tinea (pityriasis) vesicolor, Malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.Type: GrantFiled: December 11, 2015Date of Patent: January 17, 2017Assignee: UNIVERSITY OF KANSASInventors: Mehmet Tanol, Scott Weir
-
Patent number: 9545414Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: GrantFiled: March 6, 2015Date of Patent: January 17, 2017Assignee: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLCInventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Patent number: 9545415Abstract: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.Type: GrantFiled: January 4, 2013Date of Patent: January 17, 2017Inventors: Toshihisa Kawai, Kenneth I. Kohn
-
Patent number: 9545416Abstract: The present invention relates to pharmaceutical compositions and combination therapies for treating patients having a neoplasm or a proliferative disorder, the combination comprises an inhibitor of the e1F4E gene product, such as ribavirin, and a chemotherapeutic agent, such as cytarabine, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides for the use of a combination therapy for treating patients having a neoplasm, a proliferative disorder, pre-neoplasm or a precancerous lesion, comprising an inhibitor of the e1F4E gene product, a chemotherapeutic agent, and a therapeutically effective amount of a hedgehog pathway inhibitor, such as GDC-0449; and the method of using said combination therapy.Type: GrantFiled: September 13, 2012Date of Patent: January 17, 2017Assignee: Universite de MontrealInventors: Katherine Borden, Hiba Zahreddine, Biljana Culjkovic Kraljacic
-
Patent number: 9545417Abstract: The presently disclosed subject matter relates to methods of inhibiting cancer stem cells and growth of aggressive and/or poorly differentiated metastatic tumors comprising the cancer stem cells with HMGA1 inhibitors. The presently disclosed subject matter also provides methods of selecting and treating a subject with aggressive and/or poorly differentiated metastatic cancer using HMGA1 inhibitors.Type: GrantFiled: May 1, 2015Date of Patent: January 17, 2017Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Linda M. Smith Resar, David Huso, Leslie Cope
-
Patent number: 9545418Abstract: The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction of stabilization of at least one sign or symptom of cancer.Type: GrantFiled: February 17, 2015Date of Patent: January 17, 2017Assignee: The Johns Hopkins UniversityInventors: Antonio Jimeno, Manuel Medina Hidalgo
-
Patent number: 9545419Abstract: A method and composition for treating chronic inflammatory disorders comprising a pharmaceutically acceptable carrier suitable for oral administration or injection and containing a therapeutic amount of a complex of dietary supplement ingredients comprising nicotinamide, quercetin, curcumin, EPA, DHA, hesperetin and glychrrhizin.Type: GrantFiled: November 24, 2015Date of Patent: January 17, 2017Assignee: ELORAC INCInventor: Joel E Bernstein
-
Patent number: 9545420Abstract: Disclosed is a method of promoting wound healing or wound closure. The method comprises administration of a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide. Also disclosed are method of treating chronic cutaneous wounds, method of identifying a non-healing wound, use and a pharmaceutical composition comprising a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide.Type: GrantFiled: July 29, 2013Date of Patent: January 17, 2017Assignee: Agency for Science, Technology and ResearchInventor: Prabha Sampath
-
Patent number: 9545421Abstract: A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 5 nm. Methods of making the nucleic acid-delivery vehicle and kits comprising nucleic acid-delivery vehicle are also provided.Type: GrantFiled: May 4, 2010Date of Patent: January 17, 2017Assignee: GENERAL ELECTRIC COMPANYInventors: John Richard Nelson, Timothy James Yosenick
-
Patent number: 9545422Abstract: The present disclosure provides neuromodulators, nucleic acid encoding thereof, and compositions thereof for endowing visual processing abilities to neuronal cells. The present disclosure further provides a method of restoring light sensitivity to degenerate retinas.Type: GrantFiled: February 14, 2011Date of Patent: January 17, 2017Assignee: The Regents of the University of CaliforniaInventors: Kenneth P. Greenberg, Frank Werblin
-
Patent number: 9545423Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.Type: GrantFiled: December 23, 2013Date of Patent: January 17, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo
-
Patent number: 9545424Abstract: The invention relates to a method for enhancing a surfactant, in particular a pulmonary surfactant, as well as a method for producing a surfactant enhancement agent, in particular a pulmonary surfactant enhancement agent. The invention also relates to a surfactant enhancement agent and a use of an enhancement agent for enhancing a surfactant, in particular, a pulmonary surfactant. Further, the invention relates to a method of mitigating oxidative damage to pulmonary surfactant by adding a cholesterol-sequestrating agent such as cyclodextrin. Finally, a method is provided for treating a patient having surfactant dysfunction due to oxidative damage to pulmonary surfactant by administering a surfactant-protective amount of a cholesterol-sequestrating agent to protect the surfactant from the negative effects of oxidative degradation.Type: GrantFiled: September 27, 2012Date of Patent: January 17, 2017Assignee: SolAero Med Inc.Inventors: Matthias W. Amrein, Lasantha C. Gunasekara, Ryan Pratt
-
Patent number: 9545425Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.Type: GrantFiled: February 24, 2016Date of Patent: January 17, 2017Assignee: Ardelyx, Inc.Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
-
Patent number: 9545426Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.Type: GrantFiled: July 29, 2015Date of Patent: January 17, 2017Assignee: Acacia Pharma LimitedInventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
-
Patent number: 9545427Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.Type: GrantFiled: March 9, 2015Date of Patent: January 17, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Janice Marie Brown
-
Patent number: 9545428Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: GrantFiled: May 20, 2015Date of Patent: January 17, 2017Assignees: The Texas A&M University System, Temple Therapeutics, Inc.Inventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz
-
Patent number: 9545429Abstract: Homeopathic compositions. Implementations of topical homeopathic compositions may include an actives portion including a plurality of active ingredients and a base including a plurality of inactive ingredients where the plurality of active ingredients include tinctures and/or homeopathic preparations of Actaea spicata, Aesculus hippocastanum, Arnica montana, Atropa belladonna, Bellis perennis, Bryonia alba, Calendula officinalis, Causticum, Cimicifuga racemosa, Hypericum perforatum, Kali Carbonicum, Ledum palustre, Lithium Carbonicum, Rhododendron chrysanthum, Rhus toxicodendron, Ruta graveolens, Salicylicum Acidum, and Stellaria media and one or more tinctures and/or homeopathic preparations selected from the group consisting of Althaea officinalis, Caulophyllum thalictroides, Guaiacum, Rhamnus californica, or any combination thereof.Type: GrantFiled: September 3, 2011Date of Patent: January 17, 2017Assignee: BIOLYTE LABORATORIES, LLCInventor: Daniel J. Kaline
-
Patent number: 9545430Abstract: This invention relates to a Siraitiae fructus product and a method for preparing the same. The product uses a Siraitiae fructus seed as a carrier, and Siraitiae fructus flesh is coated on the carrier. The flesh may the original flesh tissue, or flesh pulp prepared through a physical method. The product is convenient for eating, and has a distinct flavor and a high amount of active ingredients. The preparation method is simple and practical, and significantly reduces energy consumption.Type: GrantFiled: February 17, 2013Date of Patent: January 17, 2017Inventor: Qingyang Wang
-
Patent number: 9545431Abstract: The routine use of antibiotics to battle Streptococcal pathogens has produced a new class of superbug—multi-drug resistant streptococci resulting in a need for new antimicrobials. The LambdaSa2 prophage endolysin gene harbors an amidase-5 (endopeptidase), an amidase-4 (glycosidase) domain and two Cpl-7 cell wall-binding domains. This endolysin can digest the cell walls of Streptococcus agalactiae, Streptococcus pneumoniae and Staphylococcus aureus. Turbidity reduction and plate lysis assays indicate that this peptidoglycan hydrolase also shows strong lytic activity toward Streptococcus pyogenes, Streptococcus dysgalactiae, Streptococcus uberis, Streptococcus equi, GES, and GGS.Type: GrantFiled: May 21, 2009Date of Patent: January 17, 2017Assignee: The United States of America, as Represented by the Secretary of AgricultureInventor: David M. Donovan
-
Patent number: 9545432Abstract: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.Type: GrantFiled: May 7, 2010Date of Patent: January 17, 2017Assignee: Spinalcyte, LLCInventors: Lionel C. Sevrain, Sylvie Y. Verdier-Sevrain
-
Patent number: 9545433Abstract: Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making anybodies to myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.Type: GrantFiled: November 25, 2015Date of Patent: January 17, 2017Assignee: The Johns Hopkins UniversityInventors: Guang William Wong, Marcus Michael Seldin
-
Patent number: 9545434Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.Type: GrantFiled: June 19, 2015Date of Patent: January 17, 2017Assignee: NPS PHARMACEUTICALS, INC.Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
-
Patent number: 9545435Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.Type: GrantFiled: October 5, 2016Date of Patent: January 17, 2017Assignee: NPS PHARMACEUTICALS, INC.Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
-
Patent number: 9545436Abstract: The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor VII (rFVIIa), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rFVIIa.Type: GrantFiled: March 14, 2014Date of Patent: January 17, 2017Assignees: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Ernst Böhm, Michael Dockal, Andrea Sedivy
-
Patent number: 9545437Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.Type: GrantFiled: March 24, 2015Date of Patent: January 17, 2017Assignee: OncoTherapy Science, Inc.Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
-
Patent number: 9545438Abstract: The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the effect of a viral inactivation procedure on the antigenicity of the inactivated virus, in particular, for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods to determine the antigenicity of an inactivated virus as well as methods to screen for anti-viral compounds using any one of the aforementioned methods. Methods of using the inactivated and immunogenic virus thus obtained, in particular, in the manufacture of a vaccine, are also provided by the present invention.Type: GrantFiled: February 27, 2009Date of Patent: January 17, 2017Assignee: Universiteit GentInventors: Peter Delputte, Hans Nauwynck, Iris Delrue, Merijn Vanhee
-
Patent number: 9545439Abstract: Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier.Type: GrantFiled: February 10, 2015Date of Patent: January 17, 2017Assignee: Zoetis Services LLCInventors: Evan James Diehl, David Leon Lutz, Jeffrey Harold Rodenberg, Mahesh Kumar
-
Patent number: 9545440Abstract: An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T1 (b) a denaturing distillation carried out at a temperature T2; wherein steps (a) and (b) may be performed in either order; T1 and T2 are sufficient to cause squalene to boil; T2>T1; and T2>200° C.Type: GrantFiled: October 23, 2015Date of Patent: January 17, 2017Assignee: NOVARTIS AGInventor: Maninder Hora
-
Patent number: 9545441Abstract: Glycated hemoglobin (HbA1c) levels and other characteristics of diabetes are reduced by administering to a human subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.Type: GrantFiled: September 18, 2013Date of Patent: January 17, 2017Assignee: XBiotech, Inc.Inventor: John Simard
-
Patent number: 9545442Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: July 31, 2015Date of Patent: January 17, 2017Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Patent number: 9545443Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.Type: GrantFiled: July 18, 2014Date of Patent: January 17, 2017Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Patent number: 9545444Abstract: Cancer treatment is provided, by irradiating an individual with a localized, high single dose or short course of doses at a primary tumor site; collecting T cells from the individual after a period of time sufficient activation of an anti-tumor response; treating the individual with an effective dose of dose of chemotherapy; and reintroducing the T cell population back to the individual.Type: GrantFiled: June 25, 2015Date of Patent: January 17, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Samuel Strober, Alexander Filatenkov
-
Patent number: 9545445Abstract: The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients: (a) a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof; (b) at least one compound or a pharmaceutically acceptable salt thereof selected from the group consisting of calcium antagonists, renin-angiotensin system inhibitors, diuretics, sympatholytic agents, vasodilators, and medicinally acceptable salts of these. The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.Type: GrantFiled: June 25, 2010Date of Patent: January 17, 2017Assignee: Teijin Pharma LimitedInventors: Takashi Shirakura, Mizuho Tamura, Yoshimasa Takahashi, Ippei Kuwahara
-
Patent number: 9545446Abstract: This invention provides a method of colonic cleansing.Type: GrantFiled: February 25, 2014Date of Patent: January 17, 2017Assignee: SYNERGY PHARMACEUTICALS, INC.Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
-
Patent number: 9545447Abstract: The present disclosure generally relates to polymer-drug systems, and more particularly to nanoscopic particles comprising amphiphilic block copolymers conjugated, physically encapsulated, or otherwise combined with chemotherapeutic agents along a selective region or regions of the backbone of the copolymer, so as to package the chemotherapeutic agent in selective domains within each nanoscopic particle, as well as to methods for making such particles, and applications and methods for using such particles, including in the formation of polymer micelles.Type: GrantFiled: October 1, 2013Date of Patent: January 17, 2017Assignee: The Texas A&M University SystemInventors: Karen Wooley, Jiong Zou, Mahmoud El Sabahy, Shiyi Zhang, Fuwu Zhang
-
Patent number: 9545448Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.Type: GrantFiled: March 27, 2015Date of Patent: January 17, 2017Assignee: Purdue Pharma L.P.Inventors: Debora Guido, Haiyong Hugh Huang
-
Patent number: 9545449Abstract: The present invention relates to the formation of protein conjugates from proteins chemically modified for linkage to (1) anticancer drug pharmacophores, (2) ligands to biomarkers on cancer cell surfaces, (3) and/or another protein molecule. It provides and specifies new compositions, methods and combinations for tumor, and tumor vasculature targeting and cancer treatment.Type: GrantFiled: May 13, 2013Date of Patent: January 17, 2017Assignee: Advanced Proteone Therapeutics Inc.Inventor: Alexander Krantz
-
Patent number: 9545450Abstract: Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (N)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (N)-terminus on a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the IGF2/CI-MPR receptor and cellular uptake using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.Type: GrantFiled: May 25, 2012Date of Patent: January 17, 2017Assignee: Amicus Therapeutics Inc.Inventor: Hung Do
-
Patent number: 9545451Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: GrantFiled: October 31, 2014Date of Patent: January 17, 2017Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino, William C. Olson, Yashu Liu
-
Patent number: 9545452Abstract: Drug carriers, methods of synthesizing, and methods of use thereof are provided. The drug carriers are liposomes comprising at least one functionalized cholesterol of the formula: Chol-X-T, wherein X is a linker domain, T is at least one targeting moiety which binds hard tissue and/or medical implants, and Chol is cholesterol or a derivative or analog thereof. The liposomes may encapsulate at least one therapeutic agent for the treatment of an oral disease or disorder.Type: GrantFiled: February 7, 2011Date of Patent: January 17, 2017Assignee: Board of Regents of the University of NebraskaInventors: Dong Wang, Xin-Ming Liu
-
Patent number: 9545453Abstract: The present invention generally relates to carriers including polymers and lipids that comprise a CXCR4 inhibiting moiety. More specifically, these carriers are biodegradable and can be bioreducible polymers that comprise a CXCR4 inhibiting moiety. These carriers can be suitable for delivery of nucleic acids to cells. These carriers and pharmaceutical compositions can be used to treat various conditions including cancers and inflammation conditions.Type: GrantFiled: October 15, 2012Date of Patent: January 17, 2017Assignee: Wayne State UniversityInventors: David Oupicky, Jing Li
-
Patent number: 9545454Abstract: Isolated polynucleotides comprising a S100B mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.Type: GrantFiled: July 24, 2015Date of Patent: January 17, 2017Assignee: The University of British ColumbiaInventors: Elizabeth M. Simpson, Charles de Leeuw, Wyeth W. Wasserman, Daniel Goldowitz
-
Patent number: 9545455Abstract: A method and device for the diagnosis of gastrointestinal allergy. The method and the device expose a surface to at least one antigen at a fixed depth. The device includes an application point each having an antigen allowing for the application of the antigen to the surface at a fixed depth. The device may include multiple applications points each with an antigen for simultaneously applying the antigens to the surface.Type: GrantFiled: April 29, 2010Date of Patent: January 17, 2017Inventor: Pravin K. Muniyappa
-
Patent number: 9545456Abstract: Provided herein are dual contrast agents or nanocomposite particles designed to enhance optoacoustic-ultrasonic imaging. The contrast agents or particles have a core designed to enhance response to incident transient ultrasonic pressure waves and at least two layers disposed around the core. The inner first layer is designed to effectively absorb incident transient optical waves, convert absorbed optical energy into heat and demonstrates significant thermal expansion and/or conversion of thermal energy into acoustic pressure. The outer second layer thermally insulates the inner layer from the surrounding aqueous environment and enhances the generation of transient ultrasonic pressure waves during optoacoustic-ultrasonic imaging and sensing. Also provided are methods of enhancing contrast in a tissue optoacoustic-ultrasonic imaging and producing enhanced optoacoustic images by contacting the tissue with the dual contrast agent or nanocomposite particles.Type: GrantFiled: February 22, 2013Date of Patent: January 17, 2017Assignee: TomoWave Laboratories, Inc.Inventors: Alexander A Oraevsky, Anton Liopo, Sergey A Ermilov
-
Patent number: 9545457Abstract: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.Type: GrantFiled: February 24, 2014Date of Patent: January 17, 2017Assignee: Lantheus Medical Imaging, Inc.Inventors: Poh K. Hui, John E. Bishop, Eleodoro S. Madrigal, Jr.